Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
ConditionOvarian Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age19-80
SponsorNational Cancer Center, Korea
About this trial
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
Eligibility criteria
Qualifiers
Patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Patients with recurrent ovarian cancer who have received platinum-based chemotherapy (3 or 4 cycles) and were deemed unsuitable for secondary cytoreductive surgery due to a negative AGO score according to the DESKTOP-III trial.
Patients with recurrent ovarian cancer who have responded to chemotherapy (Complete Response, Partial Response, or Stable Disease).
The patient's disease must have recurred after platinum-based therapy, and be defined as platinum-sensitive, meaning progression occurred more than 6 months (180 days) after the last administration of platinum-based therapy.
Disqualifiers
Patients with non-epithelial ovarian cancer or borderline ovarian tumors.
Patients with recurrent ovarian cancer who are not suitable for platinum-based chemotherapy.
Patients over 80 years of age.
Patients with a clinically assessed life expectancy of less than 3 months.
Trial design
Treatments tested in this trial
- Secondary Cytoreductive Surgery
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov